

2409 5 JUL 18 A9:42
JUL 15 2005

The Weinberg Group Inc.
Attention: Nicholas M. Fleischer, Ph.D.
1220 Nineteenth Street, NW, Suite 300
Washington, DC 20036-2400

Docket No. 2005P-0225/CP1

Dear Dr. Fleischer:

This is in response to your petition filed on June 10, 2005, requesting permission to file an Abbreviated New Drug Application (ANDA) for the following drug products: Oxycodone Hydrochloride Extended-release Tablets, 30 mg and 60 mg. The listed drug products to which you refer in your petition are OxyContin® (Oxycodone Hydrochloride) Extended-release Tablets, 10 mg, 20 mg, 40 mg and 80 mg, approved under NDA 20-553 held by Purdue Pharma, L.P. Please note that the regulations require that you identify a listed drug. We note that in your petition you reference the availability of four strengths. The reference-listed drug identified in Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) is OxyContin Extended-release Tablets, 40 mg.

Your request involves a change in strengths from that of the listed drug products (i.e., the addition of two intermediate strengths of 30 mg and 60 mg). The change you request is the type of change that is authorized under the Federal Food, Drug, and Cosmetic Act (Act).

We have reviewed your petition under Section 505(j)(2)(C) of the Act and have determined that it is approved. This letter represents the Food and Drug Administration's (FDA) determination that an ANDA may be submitted for the above-referenced drug products.

Under Section 505(j)(2)(C)(i) of the Act, the FDA must approve a petition seeking a strength that differs from the strength of the listed drug product unless it finds that investigations must be conducted to show the safety and effectiveness of the differing strength.

The FDA finds that the change in strengths for the specific proposed drug products does not pose questions of safety or effectiveness because the uses, dose, dosage form and route of administration of the proposed drug products are the same as that of the listed drug products. The FDA concludes, therefore, that investigations are not necessary in this instance. In addition, if shown to meet bioavailability requirements, the proposed drug products can be expected to have the same therapeutic effect as the listed reference drug products.

2005P-0225

PAV 1

Docket No. 2005P-0225/CP1
The Weinberg Group Inc.
Oxycodone Hydrochloride Extended-release Tablets, 30 mg and 60 mg

The approval of your suitability petition to allow an ANDA to be submitted for the above-referenced drug products does not mean that the FDA has determined that an ANDA will be approved for the drug products. The determination of whether an ANDA will be approved is not made until the ANDA itself is submitted and reviewed by the FDA.


To permit review of your ANDA submission, you must submit all information required under Sections 505(j)(2)(A) and (B) of the Act. To be approved, the drug products will, among other things, be required to meet current bioavailability requirements under Section 505(j)(2)(A)(iv) of the Act. We suggest that you submit your protocol for the drug products to the Office of Generic Drugs, Division of Bioequivalence, prior to the submission of your ANDA. During the review of your application, the FDA may require the submission of additional information.

For your information, the listed drug products to which you refer are covered by patents which appear in the Approved Drug Products With Therapeutic Equivalence Evaluations, 25th Edition, published by the Agency. The existence of such patents will require a certification upon submission of an ANDA for your proposed drug products and may also affect the approval date of any ANDA.

The listed drug product to which you refer in your ANDA must be the same drug product upon which you based this petition. In addition, you should refer in your ANDA to the appropriate petition docket number cited above, and include a copy of this letter in the ANDA submission. Please note that once an application is approved for a drug product that is the same as the subject of this petition, that drug product will be a listed drug. Thereafter, the petition may not be utilized as the basis for submission of an ANDA.

A copy of this letter approving your petition will be placed on public display in the Dockets Management Branch, Room 1061, Mail Stop HFA-305, 5630 Fishers Lane, Rockville, MD 20852.

Sincerely yours,



Gary J. Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research